Exit Hollyport Capital
also invests · investor profileLondon, GB · 1 known investors
Hollyport is an adviser of global private equity assets, acquiring mature portfolios in the secondary market from longstanding investors and restructuring individual funds to address stakeholder misalignments. The firm serves institutions, family offices, endowments, and high net worth individuals.
Also known as Hollyport · Hollyport Capital
Investors · 1
Company profile
researched Aug 2026Hollyport Capital is a manager of global private equity assets acquired in the secondary market. The firm provides liquidity to investors seeking to realise mature private equity investments, acquiring portfolios that span a wide range of fund types and geographies.
The firm has raised and invested seven secondary private equity funds since 2006 and in December 2022 closed Hollyport Secondary Opportunities Fund VIII, which secured over $2.2bn of commitments across the main fund and an overage vehicle, exceeding its $1.5bn target. Fund VIII made its first investment in March 2022. At the time of that close Hollyport reported over $4.7bn of assets under management; its website reports $11bn under management. Hollyport has also held direct company positions, including a stake in the UK contact lens manufacturer Sauflon Pharmaceuticals that it sold to CooperVision in 2014.
Business model
Hollyport raises and manages closed-end secondaries funds that acquire mature private equity fund interests and portfolios from existing investors, generating returns by realising the underlying assets over time. Since 2006 it has raised and invested seven secondary private equity funds, with an eighth, Hollyport Secondary Opportunities Fund VIII, closing in December 2022.
Traction
Seven secondary private equity funds raised and invested since 2006 plus a 2022 close of Fund VIII at over $2.2bn of commitments; over $4.7bn of assets under management as of December 2022 and $11bn under management per the company website.
Latest developments
Hollyport closed Hollyport Secondary Opportunities Fund VIII in December 2022 with over $2.2bn of commitments across the main fund and overage vehicle, above its $1.5bn target; the fund made its first investment in March 2022 and had entered acquisition agreements accounting for roughly 15% of its target investment programme by the December announcement.
▸Full profile — market position, go-to-market, geography, history
Market position
Hollyport is described as a leading investor making mature private equity investments on the secondary market, and is named alongside secondary buyers such as Ardian, Apollo, Lexington Partners and Strategic Partners.
Hollyport focuses specifically on legacy and mature private equity assets, with a stated heritage in that segment of over 30 years and a track record across eight secondaries funds. Its 2014 exit from Sauflon Pharmaceuticals returned over 60 times initial investment at an IRR in excess of 80%.
Go-to-market
The firm sources transactions from institutional investors and holders of mature private equity fund interests seeking liquidity, and raises capital through institutional commitments to successive closed-end secondaries funds, supported by external advisers including Proskauer on fund formation and Jamieson Corporate Finance on exits.
Institutional investors and limited partners seeking to realise mature or legacy private equity fund investments, plus institutional investors committing capital to Hollyport's secondaries funds.
Geography
Hollyport acquires private equity fund portfolios across a wide range of geographies. Its fund formation work in 2022 was led from London, and its 2014 Sauflon transaction involved a London-based portfolio company with manufacturing operations in Hungary.
History
Hollyport has raised and invested secondary private equity funds since 2006 and describes a heritage in the legacy private equity market stretching back over 30 years. In 2014 it sold its shareholding in contact lens manufacturer Sauflon Pharmaceuticals to CooperVision in a transaction valued at approximately $1.2bn, realising more than 60 times its initial investment and an IRR in excess of 80% over a seven-year holding period; Jamieson Corporate Finance advised on the sale. In December 2022 the firm closed its eighth fund with over $2.2bn of commitments, at which point it reported over $4.7bn of assets under management. Its website reports $11bn under management.
Compiled by commissioned research from 3 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 2
launches, deals, and filingsHollyport Capital closed its eighth secondaries fund, Hollyport Secondary Opportunities Fund VIII, securing over $2.2bn of commitments across the main fund and an overage vehicle, above its $1.5bn target. Proskauer advised on the fund formation. The fund made its first investment in March 2022 and had entered acquisition agreements covering approximately 15% of its target investment programme by the announcement date.
$2.2B source ↗
Hollyport Capital sold its shareholding in contact lens manufacturer Sauflon Pharmaceuticals to CooperVision in a transaction valued at approximately $1.2bn, realising a return of over 60 times initial investment and an IRR in excess of 80% after seven years of ownership. Jamieson Corporate Finance advised Hollyport on the sale, which was subject to approval by the German competition authorities.
$1.2B source ↗
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 3
primary sources listed
- Exit Hollyport Capitalhollyportcapital.com · web
3 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Exit Hollyport Capital do?
- Hollyport Capital is a secondaries manager that buys mature private equity fund portfolios, providing liquidity to existing investors.
- Who are Exit Hollyport Capital's investors?
- Exit Hollyport Capital's investors include BLN Capital.
- Where is Exit Hollyport Capital headquartered?
- Exit Hollyport Capital is headquartered in London, GB.